logo-loader
viewProactive Group

PDS Biotechnology shares pop on positive medical journal article

The article explains how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells

Blood cells
The article explored how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) exploded Wednesday on news that an article supporting its signature cancer treatment platform will be published in the Journal of Immunology’s June issue.

The article explains how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells, while making the cancer cells more vulnerable to attack.

The New Jersey company’s stock soared 43% to US$8.80.

The piece examines a preclinical study conducted at University of Kentucky School of Medicine, which corroborated the results of earlier preclinical studies regarding the immunological activity of PDS’ proprietary lipid molecule.

"As a cancer immunologist who has spent the last decade performing translational and clinical research in immuno-oncology at the National Cancer Institute, the versatility of PDS’ Versamune technology, and the strength of this recently published data, demonstrates Versamune’s potential to provide significant advancements in the treatment of various cancers and debilitating diseases,” said Chief Medical Officer Lauren Wood. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks back in the red but make gains overall...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, sank 4.4% at 123 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF lost 5.8% to C$9.55, while the OTCQX Cannabis retreated 4% at...

8 hours, 10 minutes ago

2 min read